Your SlideShare is downloading. ×
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

62

Published on

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies …

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies
@ http://www.researchmoz.us/solid-tumors-market-in-asia-pacific-to-2019-new-drug-approvals-and-anticipated-product-launches-to-trigger-a-shift-in-treatment-paradigm-to-targeted-therapies-report.html

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
62
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types. The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition. Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four APAC markets of Australia, China, India and Japan. The report includes: Disease overview, as well as treatment algorithms and treatment usage patterns Market size and forecast for the APAC solid tumors market from 2012 to 2019 Major marketed products in the APAC region for all four solid tumor types covered In-depth pipeline analysis for all four solid tumor types Key drivers and restraints that have had and are expected to have a significant impact upon the market Key licensing and co-development agreements in the solid tumors market Reasons to Buy The report will enhance your decision-making capability by allowing you to: Align your product portfolio to the markets with high growth potential Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the solid tumors market Develop key strategic initiatives based upon an understanding of key focus areas and leading companies Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships table Of Content Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
  • 2. 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures 2 Solid Tumors Market In Asia Pacific To 2019 - Introduction 2.1 Introduction 3 Solid Tumors Market In Asia Pacific To 2019 - Therapeutic Landscape 3.1 Bladder Cancer 3.1.1 Symptoms 3.1.2 Etiology 3.1.3 Pathophysiology 3.1.4 Diagnosis 3.1.5 Classification 3.1.6 Epidemiology 3.1.7 Prognosis And Disease Staging 3.1.8 Treatment Options 3.2 Ovarian Cancer 3.2.1 Symptoms 3.2.2 Etiology 3.2.3 Pathophysiology 3.2.4 Diagnosis 3.2.5 Classification 3.2.6 Epidemiology 3.2.7 Prognosis And Disease Staging 3.2.8 Treatment Options 3.3 Pancreatic Cancer 3.3.1 Symptoms 3.3.2 Etiology 3.3.3 Pathophysiology 3.3.4 Diagnosis 3.3.5 Classification 3.3.6 Epidemiology 3.3.7 Prognosis And Disease Staging 3.3.8 Treatment Algorithm 3.4 Prostate Cancer 3.4.1 Symptoms 3.4.2 Etiology 3.4.3 Pathophysiology 3.4.4 Co-morbidities And Complications 3.4.5 Diagnosis Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
  • 3. 3.4.6 Classification 3.4.7 Epidemiology 3.4.8 Prognosis And Disease Staging 3.4.9 Treatment Options 4 Solid Tumors Market In Asia Pacific To 2019 - Marketed Products 4.1 Bladder Cancer 4.2 Ovarian Cancer 4.3 Pancreatic Cancer 4.4 Prostate Cancer 4.5 Key Marketed Products 4.5.1 Carboplatin 4.5.2 Cisplatin 4.5.3 Gemcitabine 4.5.4 Paclitaxel 4.5.5 Doxorubicin 4.5.6 Avastin (bevacizumab) 4.5.7 Tarceva (erlotinib) 4.5.8 Sutent (sunitinib) 4.5.9 Afinitor (everolimus) 4.5.10 Taxotere (docetaxel) 4.5.11 Zytiga (abiraterone Acetate) 4.5.12 Jevtana (cabazitaxel) 5 Solid Tumors Market In Asia Pacific To 2019 - Pipeline Analysis 5.1 Bladder Cancer Pipeline 5.1.1 Overall Pipeline 5.1.2 Pipeline Analysis By Molecule Type 5.1.3 Pipeline Analysis By Mechanism Of Action 5.2 Ovarian Cancer Pipeline 5.2.1 Overall Pipeline 5.2.2 Pipeline Analysis By Molecule Type 5.2.3 Pipeline Analysis By Mechanism Of Action 5.3 Pancreatic Cancer Pipeline 5.3.1 Overall Pipeline 5.3.2 Pipeline Analysis By Molecule Type 5.3.3 Pipeline Analysis By Mechanism Of Action 5.4 Prostate Cancer Pipeline 5.4.1 Overall Pipeline 5.4.2 Pipeline Analysis By Molecule Type 5.4.3 Pipeline Analysis By Mechanism Of Action Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
  • 4. 5.5 Promising Drug Candidates In The Pipeline 5.5.1 Abraxane (albumin-bound Paclitaxel) 5.5.2 Amg 386 (trebananib) 5.5.3 Votrient (pazopanib) 5.5.4 Xtandi (enzalutamide) 6 Solid Tumors Market In Asia Pacific To 2019- Market Forecast 6.1 Asia-pacific Market 6.1.1 Treatment Usage Patterns 6.1.2 Annual Cost Of Treatment 6.1.3 Market Size 6.2 India 6.2.1 Treatment Usage Patterns 6.2.2 Annual Cost Of Treatment 6.2.3 Market Size 6.3 Australia 6.3.1 Treatment Usage Patterns 6.3.2 Annual Cost Of Treatment 6.3.3 Market Size 6.4 China 6.4.1 Treatment Usage Patterns 6.4.2 Annual Cost Of Treatment 6.4.3 Market Size 6.5 Japan 6.5.1 Treatment Usage Patterns 6.5.2 Annual Cost Of Treatment 6.5.3 Market Size 6.6 Drivers And Barriers For The Solid Tumors Market In Apac 6.6.1 Drivers 6.6.2 Barriers 7 Solid Tumors Market In Asia Pacific To 2019 - Deals And Strategic Consolidations 7.1 Deals Analysis 7.2 Major Co-development Deals 7.2.1 Scinopharm Taiwan And Coland Enter Into Agreement To Develop Generic Oncological Drugs 7.2.2 Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 7.2.3 Merck Enters Into Co-development Agreement With Endocyte For Cancer Drug 7.2.4 Merck Serono Enters Into Co-development Agreement With Threshold Pharma For Th-302, pancreatic Cancer Drug 7.2.5 Seattle Genetics Exercises Option For Co-development Agreement With Agensys (affiliate Of astellas) For Asg-15me Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
  • 5. 7.3 Major Licensing Deals 7.3.1 Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 7.3.2 Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For Ff284 7.3.3 Baxter International Enters Into Licensing Agreement With Onconova Therapeutics For rigosertib 7.3.4 Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 7.3.5 Medigene Extends Licensing Agreement With Syncore For Endotag-1 8 Solid Tumors Market In Asia Pacific To 2019 - Appendix 8.1 Pipeline Drugs By Phase 8.1.1 Phase Iii 8.1.2 Pre-registration/nda-filed 8.2 Market Forecasts To 2018 8.2.1 Apac 8.2.2 Australia 8.2.3 China 8.2.4 India 8.2.5 Japan 8.3 Market Definitions 8.4 Abbreviations 8.5 Sources 8.6 Research Methodology 8.6.1 Coverage 8.6.2 Secondary Research 8.6.3 Primary Research 8.6.4 Therapeutic Landscape 8.6.5 Geographical Landscape 8.6.6 Pipeline Analysis 8.7 Expert Panel Validation 8.8 Contact Us 8.9 Disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad
  • 6. Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Parad

×